Compare Charles River Laboratories Intl. Inc (CRL) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Eni SpA — how do they compare? Charles River Laboratories Intl. Inc trades at $232.76 (market cap $11.14B), while Eni SpA trades at $49.05 (market cap $71.95B). The key difference: Eni SpA is far larger — about 6.5× Charles River Laboratories Intl. Inc's market cap, and Eni SpA pays a 4.93% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | E | |
|---|---|---|
Market Cap | $11.14B | $71.95B |
Sector | Health | Energy |
52-Week High | $233.60 | $57.61 |
52-Week Low | $145.57 | $32.93 |
Enterprise Value | $14.00B | $90.86B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Eni (E) trades at $49.44, up 3.6% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 21.81 and P/S of 0.8, though revenue has declined from $132.5B in 2022 to $82.15B in 2025. Recent strategic moves include lithium investments in Chile, fusion energy partnerships, and global gas portfolio expansion. The company maintains positive cash flow with $238M net cash flow in 2025 and pays a $0.63 dividend.
Eni presents a mixed outlook with strong diversification efforts offset by declining revenue trends. The stock offers value characteristics with below-market valuations and dividend income, but faces headwinds from volatile energy markets and execution risks in new ventures. Analyst consensus leans cautious with 62% hold ratings, suggesting patience may be warranted despite current bullish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
